Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma‐derived products

Vox Sanguinis - Tập 87 Số 1 - Trang 10-18 - 2004
Kathryn Martin Remington1, Stephen J. Trejo1, G. Buczynski1, H. Li1, Wendy P. Osheroff1, J. P. Brown1, Hilton Renfrow1, Richard Reynolds1, Dominique Pifat1
1Preclinical Research and Pathogen Safety, Biological Products Division, Bayer Health Care, LLC, Research Triangle Park, NC, USA

Tóm tắt

Background and Objectives  Human plasma is the source of a wide variety of therapeutic proteins, yet it is also a potential source of viral contamination. Recent outbreaks of emergent viral pathogens, such as West Nile virus, and the use of live vaccinia virus as a vaccine have prompted a reassessment of the viral safety of plasma‐derived products. The purpose of this study was to evaluate the efficacy of current viral inactivation methods for West Nile and vaccinia viruses and to reassess the use of model viruses to predict inactivation of similar viral pathogens.

Materials and Methods  Virus‐spiked product intermediates were processed using a downscaled representation of various manufacturing procedures. Virus infectivity was measured before and after processing to determine virus inactivation.

Results  The results demonstrated effective inactivation of West Nile virus, vaccinia virus and a model virus, bovine viral diarrhoea virus, during pasteurization, solvent/detergent treatment and caprylate treatment. Caprylate provided rapid and effective inactivation of West Nile virus, vaccinia virus, duck hepatitis B virus and Sindbis virus. Inactivation of West Nile virus was similar to that of bovine viral diarrhoea virus.

Conclusions  This study demonstrates that procedures used to inactivate enveloped viruses in manufacturing processes can achieve inactivation of West Nile virus and vaccinia virus. In addition, the data support the use of model viruses to predict the inactivation of similar emergent viral pathogens.

Từ khóa


Tài liệu tham khảo

CPMP:, 1996, CPMP Note for Guidance on Virus Validation Studies: the Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses.

10.1046/j.1537-2995.2003.00501.x

Center for Biologics Evaluation and Research:, 2003, Final Guidance. Revised Recommendations for the Assessment of Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection.

Center for Biologics Evaluation and Research:, 2002, Workshop on Development of Donor Screening Assays for West Nile Virus.

American Association of Blood Banks:, 2003, Recommended Guidance for Reporting West Nile Viremic Blood Donors to State and/or Local Public Health Departments and Reporting Donors Who Subsequently Develop West Nile Virus Illness to Blood Collection Agencies.

CPMP:, 2003, CPMP Position Statement on West Nile Virus and Plasma‐Derived Medicinal Products.

Centers for Disease Control and Prevention:, 2003, Updated interim CDC Guidance for Use of Smallpox Vaccine, Cidofovir, and Vaccinia Immune Globulin (VIG) for Prevention and Treatment in the Setting of an Outbreak of Monkeypox Infections.

Center for Biologics Evaluation and Research:, 2002, Final Guidance. Recommendations for Deferral of Donors and Quarantine and Retrieval of Blood and Blood Products in Recent Recipients of Smallpox Vaccine (Vaccinia virus) and Certain Contacts of Smallpox Vaccine Recipients.

10.1083/jcb.121.3.521

10.1046/j.1423-0410.2003.00279.x

10.1046/j.1423-0410.2003.00285.x

Cavalli‐Sforza L, 1969, Biometrie Grundzuge Biologisch‐Medizinischer Statistik [Biometry, the Basics of Biological and Medical Statistics], Gustav Fischer Verlag Stuttgart, 171

Anon:, 1994, Joint Announcement of the Federal Health Office and the Paul Ehrlich Institute Federal Office for Sera and Vaccines: Requirements for Validation Studies to Demonstrate the Virus Safety of Drugs Derived from Human Blood or Plasma, Federal Gazette, 84, 1

10.1046/j.1537-2995.1999.39399219280.x

10.1111/j.1423-0410.1989.tb02019.x

10.1046/j.1537-2995.2003.00496.x

10.1002/jmv.1890360311

10.1006/biol.1999.0236

10.1111/j.1423-0410.1994.tb01246.x

10.1099/0022-1317-83-12-2915

10.1016/0300-9084(96)89504-6

10.1006/biol.2002.0335

10.1111/j.1423-0410.1988.tb05140.x